Novel antibody therapeutic demonstrates potential in GVHD
Key data from a Phase II trial of a potentially…
Key data from a Phase II trial of a potentially first-in-class CSF-1R monoclonal antibody for chronic graft-versus-host disease (GVHD) has been released.